Cellectis (CLLS) Assets Average (2014 - 2026)
Cellectis' (CLLS) quarterly Assets Average came in at $307.0 million in Q1 2026, down 17.89% year-on-year from $373.8 million in Q1 2025, and down 8.07% quarter-over-quarter from $333.9 million in Q4 2025.
Cellectis (CLLS) Assets Average (2014 - 2026) Analysis & Trends
Cellectis' Assets Average history runs 13 years deep, the most recent figure standing at $307.0 million for Q1 2026.
- On a quarterly basis, Assets Average fell 17.89% year-over-year to $307.0 million in Q1 2026; TTM through Mar 2026 was $307.0 million, a 17.89% decrease from a year earlier, with the FY2025 full-year figure at $354.1 million, down 1.33% from the prior year.
- Assets Average eased to $307.0 million in Q1 2026 per CLLS's latest filing, from $333.9 million in the prior quarter.
- Across five years, Assets Average topped out at $401.5 million in Q3 2024 and bottomed at $218.7 million in Q3 2023.
- The 5-year median for Assets Average is $334.0 million (2022), against an average of $323.2 million.
- Across the five-year window, Assets Average slumped 31.97% in 2022 and jumped 83.6% in 2024, its largest moves.
- Year by year, Assets Average stood at $270.4 million in 2022, then advanced by 0.59% to $272.0 million in 2023, then surged by 43.28% to $389.7 million in 2024, then decreased by 14.33% to $333.9 million in 2025, then retreated by 8.07% to $307.0 million in 2026.
- Per Business Quant, the three latest CLLS Assets Average figures stand at $307.0 million (Q1 2026), $333.9 million (Q4 2025), and $348.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 303.40 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 65.01 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 8.37 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 41.64 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 26.06 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 40.71 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 795.91 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.30 Bn |
| 10 | Cellectis | 281.48 Mn | 95.81 Mn | - | 306.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 306.95 Mn |
| Dec 31, 2025 | 333.88 Mn |
| Sep 30, 2025 | 348.51 Mn |
| Jun 30, 2025 | 359.03 Mn |
| Mar 31, 2025 | 373.82 Mn |
| Dec 31, 2024 | 389.71 Mn |
| Sep 30, 2024 | 401.51 Mn |
| Jun 30, 2024 | 380.80 Mn |
| Mar 31, 2024 | 344.36 Mn |
| Dec 31, 2023 | 271.99 Mn |
| Sep 30, 2023 | 218.69 Mn |
| Jun 30, 2023 | 239.54 Mn |
| Mar 31, 2023 | 256.31 Mn |
| Dec 31, 2022 | 270.40 Mn |
| Sep 30, 2022 | 300.23 Mn |
| Jun 30, 2022 | 334.04 Mn |
| Mar 31, 2022 | 364.63 Mn |
| Dec 31, 2021 | 397.48 Mn |
| Sep 30, 2021 | 435.23 Mn |
| Jun 30, 2021 | 450.14 Mn |